latest breakthroughs in non-invasive glucose monitoring. Keep users updated on trials, prototype unveilings, and regulatory milestones in optical glucose sensors. Perfect for a news aggregator feed.
Latest breakthroughs in non-invasive optical glucose monitoring
Curated reading list of 9 sources covering registered human studies, physiological datasets, optical prototypes, theoretical sensor designs, and regulatory context through 15 August 2026. The reviewed evidence does not verify a post-2025 FDA clearance for a truly non-invasive optical glucose sensor; conventional minimally invasive CGM milestones are not classified here as optical or non-invasive.[1][2]
Human studies, trials, and datasets
Sources most relevant to human evaluation or data resources for non-invasive optical glucose estimation. The search found limited directly matching peer-reviewed clinical evidence, and the Raman registry entry should be checked for current recruitment and study details.
Optical prototypes and device unveilings
Recent news and technical coverage of Raman, near-infrared, and other optical prototype announcements. Some reports lack publication dates, sample sizes, detailed clinical methods, or independently verifiable validation data.
Emerging optical sensor designs
Research on next-generation optical architectures, including a 2026 surface-plasmon-resonance design. The SPR paper is a numerical and theoretical study, not a human trial or clinical validation dataset.[[cite:10]]
Regulatory context and milestone tracking
Official FDA pages useful for monitoring glucose-device clearances and regulatory developments. The listed OTC and CGM documents concern CGM regulatory activity, not verified clearance of a truly non-invasive optical glucose sensor.[[cite:12]][[cite:13]]
Scoped-search caveat: searches of ClinicalTrials.gov and selected academic indexes did not establish a robust post-2025 human-trial record specifically for optical, non-invasive glucose sensors. Prototype coverage is therefore stronger than confirmed clinical or regulatory evidence, and undated reports should be treated as preliminary.[16][17][18]
Créez votre compte pour conserver cette réponse et la reprendre plus tard.
Examinons les alternatives :
- Modifier la requête.
- Démarrer une nouvelle conversation.
- Supprimer des sources (si elles ont été ajoutées manuellement).
